Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China
Translational Breast Cancer Research · 2023-10 · 4 · 32-32
DOI: 10.21037/tbcr-23-45 ↗Kurz gefasst
Editorial in der Zeitschrift Translational Breast Cancer Research, 2023-10. Verfasst von Nino Balanchivadze und 1 weiteren Autor:innen. Beteiligte Einrichtung: Virginia Oncology Associates/US Oncology Network, Norfolk, VA, USA. Die Arbeit wurde bisher 2-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Virginia Oncology Associates/US Oncology Network, Norfolk, VA, USA.
- Ontada, Boston, MA, USA.
Zitieren
APA
Balanchivadze, N., & Robert, N. J. (2023). Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China. Translational Breast Cancer Research, 4, 32-32. https://doi.org/10.21037/tbcr-23-45
Vancouver
Balanchivadze N, Robert NJ. Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China. Translational Breast Cancer Research. 2023;4:32-32. doi:10.21037/tbcr-23-45
BibTeX
@article{Balanchivadze2023,
author = {Balanchivadze, Nino and Robert, Nicholas J},
title = {Abemaciclib-based therapy versus tucidinostat-based therapy in patients with HR+HER2− metastatic breast cancer after palbociclib progression: insights and challenges from a comparative cohort study in China},
journal = {Translational Breast Cancer Research},
year = {2023},
volume = {4},
pages = {32--32},
doi = {10.21037/tbcr-23-45}
}
EUVIMED